{"analyses":[{"groupDescription":"Bone marrow aspirate","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2028","statisticalMethod":"Fisher Exact"},{"groupDescription":"Peripheral blood","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0014","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.6","upperLimit":"79.8","value":"61.5"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"71.0","value":"28.6"},{"groupId":"OG002","lowerLimit":"36.4","upperLimit":"79.3","value":"59.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Bone marrow aspirate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.9","upperLimit":"90.4","value":"77.4"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"52.7","value":"12.5"},{"groupId":"OG002","lowerLimit":"58.8","upperLimit":"89.3","value":"76.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"title":"Peripheral blood"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"MRD-negative remission rate is defined as the percentage of participants with undetectable MRD at documented CR in participants who were MRD positive at screening as assessed by flow cytometry in bone marrow and/or peripheral blood, with requirement of confirmation of MRD negativity in the subsequent peripheral blood 12 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg) for approximately 104 weeks, followed by ibrutinib monotherapy until disease progression (PD), unacceptable toxicity or withdrawal of consent. Venetoclax was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG000","title":"Randomization Phase: Ibrutinb + Venetoclax"},{"description":"Participants were randomized to ibrutinib 560 mg and placebo for approximately 104 weeks, followed by ibrutinib monotherapy until PD, unacceptable toxicity or withdrawal of consent. Placebo was discontinued after 104 weeks of treatment, regardless of response assessment.","id":"OG001","title":"Randomization Phase: Ibrutinib + Placebo"},{"description":"Participants were treated with ibrutinib 560 mg and venetoclax (starting at 20 mg, and gradually ramped up to a target dose of 400 mg).","id":"OG002","title":"Treatment-naive Open-label Arm"}],"paramType":"NUMBER","populationDescription":"All enrolled treatment-naïve participants achieving CR who were evaluable for MRD (those who had positive MRD status at screening). Participants with a given post-screening sample.","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 61.34 months (Randomization Phase) and 40.51 months (Treatment-Naïve arm)","title":"MRD-negative Remission Rate in Participants Who Achieve CR Per Investigator Assessment (Randomization Phase and Treatment-Naive Arm)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}